Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Sonendo is offering 7,800,000 shares of its common stock. In addition, Sonendo expects to grant the underwriters a 30-day option to purchase up to an additional 1,170,000 shares of its common stock. The initial public offering price is expected to be between $15.00 and $17.00 per share. The shares are expected to trade on the New York Stock Exchange under the symbol “SONX.”

Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, and Medison Pharma Ltd., a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced an exclusive multi-regional agreement for Medison to help seek regulatory authorization and commercialize Immunocore’s tebentafusp (IMCgp100), for the treatment of patients with metastatic uveal melanoma, in Canada, twenty markets across Central Eastern Europe and Israel.

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place in multiple centers in Germany, marks the official start of the European commercial launch of Trilogy.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sonendo intends to apply to list its common stock on The New York Stock Exchange under the symbol "SONX."